ArticleBMC medicine2024
IL-2-free tumor-infiltrating lymphocyte therapy with PD-1 blockade demonstrates potent efficacy in advanced gynecologic cancer.
Article in BMC medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04766320 (A Clinical Safety and Efficacy Study on TIL for the Treatment of r/r Gynecologic Tumors), which is not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Clinical Safety and Efficacy Study on TIL for the Treatment of r/r Gynecologic Tumors
Who cites it
13 citing papers in PubMed.
- Generative AI in medicine: use and acceptance among professionals in orthopedics and traumatology: a survey-based analysis in Germany.Scientific reports · 2026Article
- PiggyBac-Engineered Membrane-Bound IL7 TILs Combined with Anti-PD-1 Antibody Demonstrates Efficacy in Recurrent Ovarian Cancer: A First-in-Human Phase I Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Cardiotoxicity of T cell immunotherapies.Nature reviews. Cardiology · 2026Review
- Advances in immunotherapies in ovarian cancer.Journal for immunotherapy of cancer · 2026Review
- CFD overexpression inhibits CESC progression and enhances TIL therapy efficacy via NOSTRIN and eNOS signaling pathway.Scientific reports · 2026Article
- Expansion of IL-2-independent tumor-infiltrating lymphocytes through a feeder-free process: a preclinical study for solid tumors.Cancer biology & medicine · 2026Article
- Characteristics and developmental trajectory of clinical trials focused on tumor-infiltrating lymphocytes for cancer treatment.Cancer gene therapy · 2026Review
- Harnessing the immune system: future directions in cancer immunotherapy.Frontiers in immunology · 2026Review
- Overcoming heterogeneity and immunosuppression: novel strategies in adoptive therapy for biliary tract cancer.Frontiers in immunology · 2026Review
- T-cell Receptor Repertoire Analysis in the Context of Transarterial Chemoembolization Synergy with Systemic Therapy for Hepatocellular Carcinoma.Journal of clinical and translational hepatology · 2025Review
- Tumor-infiltrating lymphocytes in cancer immunotherapy: from chemotactic recruitment to translational modeling.Frontiers in immunology · 2025Review
- Research progress on tumor-infiltrating lymphocyte therapy for cervical cancer.Frontiers in immunology · 2025Review
- Targeting cancer with precision: strategical insights into TCR-engineered T cell therapies.Theranostics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTumor-infiltrating lymphocyte (TIL) therapy has been restricted by intensive lymphodepletion and high-dose intravenous interleukin-2 (IL-2) administration. To address these limitations, we conducted preclinical and clinical studies to evaluate the safety, antitumor activity, and pharmacokinetics of an innovative modified regimen in patients with advanced gynecologic cancer.
methodsPatient-derived xenografts (PDX) were established from a local recurrent cervical cancer patient. TILs were expanded ex vivo from minced tumors without feeder cells in the modified TIL therapy regimen. Patients underwent low-dose cyclophosphamide lymphodepletion followed by TIL infusion without intravenous IL-2. The primary endpoint was safety; the secondary endpoints included objective response rate, duration of response, and T cell persistence.
resultsIn matched patient-derived xenografts (PDX) models, homologous TILs efficiently reduced tumor size (p < 0.0001) and underwent IL-2 absence in vivo. In the clinical section, all enrolled patients received TIL infusion using a modified TIL therapy regimen successfully with a manageable safety profile. Five (36%, 95% CI 16.3-61.2) out of 14 evaluable patients experienced objective responses, and three complete responses were ongoing at 19.5, 15.4, and 5.2 months, respectively. Responders had longer overall survival (OS) than non-responders (p = 0.036). Infused TILs showed continuous proliferation and long-term persistence in all patients and showed greater proliferation in responders which was indicated by the Morisita overlap index (MOI) of TCR clonotypes between infused TILs and peripheral T cells on day 14 (p = 0.004) and day 30 (p = 0.004). Higher alteration of the CD8
conclusionsOur modified TIL therapy regimen demonstrated manageable safety, and TILs could survive and proliferate without IL-2 intravenous administration, showing potent efficacy in patients with advanced gynecologic cancer.
trial registrationNCT04766320, Jan 04, 2021.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.